GenexGen
Private Company
Funding information not available
Overview
GenexGen is a private, preclinical-stage biotech based in Cambridge, USA, founded in 2016. The company has pivoted from its initial gene therapy focus to a novel epigenetic platform using mRNA to deliver repressors that can durably silence key immune drivers like MYD88. This approach aims to create the first targeted therapy for the rare, fatal disease HLH, while establishing a platform with potential applications in broader inflammatory and age-related conditions. The company is backed by a mix of venture capital, foundation, and government grants.
Technology Platform
mRNA-delivered epigenetic repressor platform for durable gene silencing, initially targeting the MYD88 immune signaling pathway.
Opportunities
Risk Factors
Competitive Landscape
GenexGen operates in the competitive fields of epigenetic editing and immunology. It faces competition from other gene editing companies (using CRISPR/Cas9, base editing) and biotechs targeting inflammatory pathways with antibodies or small molecules. Its differentiation lies in the combination of mRNA delivery for transient expression and durable epigenetic silencing, a relatively nascent approach.